Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

PURPOSE: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Kim, Youn H., Tavallaee, Mahkam, Sundram, Uma, Salva, Katrin A., Wood, Gary S., Li, Shufeng, Rozati, Sima, Nagpal, Seema, Krathen, Michael, Reddy, Sunil, Hoppe, Richard T., Nguyen-Lin, Annie, Weng, Wen-Kai, Armstrong, Randall, Pulitzer, Melissa, Advani, Ranjana H., Horwitz, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089160/
https://ncbi.nlm.nih.gov/pubmed/26195720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.3969
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados